264 related articles for article (PubMed ID: 33046486)
21. A critical phenylalanine residue in the respiratory syncytial virus fusion protein cytoplasmic tail mediates assembly of internal viral proteins into viral filaments and particles.
Shaikh FY; Cox RG; Lifland AW; Hotard AL; Williams JV; Moore ML; Santangelo PJ; Crowe JE
mBio; 2012; 3(1):. PubMed ID: 22318318
[TBL] [Abstract][Full Text] [Related]
22. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B.
Hause AM; Henke DM; Avadhanula V; Shaw CA; Tapia LI; Piedra PA
PLoS One; 2017; 12(4):e0175792. PubMed ID: 28414749
[TBL] [Abstract][Full Text] [Related]
23. A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.
Gaillard V; Galloux M; Garcin D; Eléouët JF; Le Goffic R; Larcher T; Rameix-Welti MA; Boukadiri A; Héritier J; Segura JM; Baechler E; Arrell M; Mottet-Osman G; Nyanguile O
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137809
[TBL] [Abstract][Full Text] [Related]
24. Respiratory syncytial virus: prospects for new and emerging therapeutics.
Jorquera PA; Tripp RA
Expert Rev Respir Med; 2017 Aug; 11(8):609-615. PubMed ID: 28574729
[TBL] [Abstract][Full Text] [Related]
25. Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.
Coates M; Brookes D; Kim YI; Allen H; Fordyce EAF; Meals EA; Colley T; Ciana CL; Parra GF; Sherbukhin V; Stockwell JA; Thomas JC; Hunt SF; Anderson-Dring L; Onions ST; Cass L; Murray PJ; Ito K; Strong P; DeVincenzo JP; Rapeport G
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652242
[TBL] [Abstract][Full Text] [Related]
26. Identification and evaluation of a novel tribenzamide derivative as an inhibitor targeting the entry of the respiratory syncytial virus.
Issmail L; Ramsbeck D; Jäger C; Henning T; Kleinschmidt M; Buchholz M; Grunwald T
Antiviral Res; 2023 Mar; 211():105547. PubMed ID: 36682463
[TBL] [Abstract][Full Text] [Related]
27. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection.
Cianci C; Genovesi EV; Lamb L; Medina I; Yang Z; Zadjura L; Yang H; D'Arienzo C; Sin N; Yu KL; Combrink K; Li Z; Colonno R; Meanwell N; Clark J; Krystal M
Antimicrob Agents Chemother; 2004 Jul; 48(7):2448-54. PubMed ID: 15215093
[TBL] [Abstract][Full Text] [Related]
28. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
[TBL] [Abstract][Full Text] [Related]
29. Genetic Stability of Parainfluenza Virus 5-Vectored Human Respiratory Syncytial Virus Vaccine Candidates after
Phan SI; Adam CM; Chen Z; Citron M; Liang X; Espeseth AS; Wang D; He B
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747497
[TBL] [Abstract][Full Text] [Related]
30. Clinical Potential of Prefusion RSV F-specific Antibodies.
Rossey I; McLellan JS; Saelens X; Schepens B
Trends Microbiol; 2018 Mar; 26(3):209-219. PubMed ID: 29054341
[TBL] [Abstract][Full Text] [Related]
31. Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.
Leemans A; De Schryver M; Van der Gucht W; Heykers A; Pintelon I; Hotard AL; Moore ML; Melero JA; McLellan JS; Graham BS; Broadbent L; Power UF; Caljon G; Cos P; Maes L; Delputte P
J Virol; 2017 Jul; 91(14):. PubMed ID: 28468888
[TBL] [Abstract][Full Text] [Related]
32. Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection.
Jordan R; Shao M; Mackman RL; Perron M; Cihlar T; Lewis SA; Eisenberg EJ; Carey A; Strickley RG; Chien JW; Anderson ML; McEligot HA; Behrens NE; Gershwin LJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4889-900. PubMed ID: 26055364
[TBL] [Abstract][Full Text] [Related]
33. Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.
Schepens B; Ibañez LI; De Baets S; Hultberg A; Bogaert P; De Bleser P; Vervalle F; Verrips T; Melero J; Vandevelde W; Vanlandschoot P; Saelens X
J Infect Dis; 2011 Dec; 204(11):1692-701. PubMed ID: 21998474
[TBL] [Abstract][Full Text] [Related]
34. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms.
Douglas JL; Panis ML; Ho E; Lin KY; Krawczyk SH; Grant DM; Cai R; Swaminathan S; Chen X; Cihlar T
Antimicrob Agents Chemother; 2005 Jun; 49(6):2460-6. PubMed ID: 15917547
[TBL] [Abstract][Full Text] [Related]
35. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
DeVincenzo J; Tait D; Efthimiou J; Mori J; Kim YI; Thomas E; Wilson L; Harland R; Mathews N; Cockerill S; Powell K; Littler E
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712214
[TBL] [Abstract][Full Text] [Related]
36. Antiviral effect of cimicifugin from Cimicifuga foetida against human respiratory syncytial virus.
Wang KC; Chang JS; Lin LT; Chiang LC; Lin CC
Am J Chin Med; 2012; 40(5):1033-45. PubMed ID: 22928833
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor.
Zheng X; Gao L; Wang L; Liang C; Wang B; Liu Y; Feng S; Zhang B; Zhou M; Yu X; Xiang K; Chen L; Guo T; Shen HC; Zou G; Wu JZ; Yun H
J Med Chem; 2019 Jul; 62(13):6003-6014. PubMed ID: 31194544
[TBL] [Abstract][Full Text] [Related]
38. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
[TBL] [Abstract][Full Text] [Related]
39. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines.
Fuentes S; Arenas D; Moore MM; Golding H; Khurana S
Vaccine; 2017 Jan; 35(4):694-702. PubMed ID: 27989627
[TBL] [Abstract][Full Text] [Related]
40. [Prospects For the Use of Peptides against Respiratory Syncytial Virus].
Shilovskiy IP; Andreev SM; Kozhikhova KV; Nikolskii AA; Khaitov MR
Mol Biol (Mosk); 2019; 53(4):541-560. PubMed ID: 31397431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
